Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
02:31:17 EDT Fri 02 May 2025
Enter Symbol
or Name
USA
CA



Q:BPTH - BIO-PATH HOLDINGS INC - https://www.biopathholdings.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
BPTH - Qnot subscribed0.15+0.014911.049.06400.15  0.16  0.13524.55  0.1215:47:2307:0015 min RT 2¢

Recent Trades - Last 10 of 40
Time ETExPriceChangeVolume
15:47:23Q0.14260.00753
15:11:52Q0.150.0149464
15:10:38Q0.15260.0175236
15:00:39Q0.15260.0175300
14:56:02Q0.152560.017461,000
14:53:19Q0.137680.002587
14:51:07Q0.160.0249175
14:50:47Q0.160.0249575
14:50:02Q0.13520.00012,400
14:48:23Q0.160.0249250

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-05-01 07:00U:BPTHNews ReleaseBio-Path Holdings Achieves Third Pre-Clinical Milestone Confirming Potential of BP1001-A as Treatment for Obesity in Type 2 Diabetes Patients
2025-03-28 07:00U:BPTHNews ReleaseBio-Path Holdings Reports Full Year 2024 Financial Results
2025-03-18 07:00U:BPTHNews ReleaseBio-Path Holdings Announces Pre-Clinical Results Signaling Increased Potential for BP1001-A as Treatment for Obesity in Type 2 Diabetes Patients
2025-02-13 16:02U:BPTHNews ReleaseBio-Path Holdings Expands Global Patent Portfolio
2025-02-13 08:00U:BPTHNews ReleaseBio-Path Holdings Provides Key Clinical Updates
2025-02-12 16:01U:BPTHNews ReleaseBio-Path Holdings Provides Update from Phase 1/1b Clinical Trial of BP1002 for Treatment of Refractory/Relapsed Acute Myeloid Leukemia
2025-01-10 07:00U:BPTHNews ReleaseBio-Path Holdings Provides 2025 Clinical and Operational Update
2024-12-19 07:00U:BPTHNews ReleaseBio-Path Holdings Announces Preclinical Testing of BP1001-A as Potential Treatment for Obesity in Type 2 Diabetes Patients Enhances Insulin Sensitivity
2024-12-13 16:45U:BPTHNews ReleaseStonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q3 24
2024-12-11 07:00U:BPTHNews ReleaseBio-Path Holdings Outlines Rationale for Development of BP1001-A as Potential Treatment for Obesity in Type 2 Diabetes Patients
2024-11-15 07:00U:BPTHNews ReleaseBio-Path Holdings Reports Third Quarter 2024 Financial Results
2024-11-08 07:00U:BPTHNews ReleaseBio-Path Holdings to Announce Third Quarter 2024 Financial Results on November 15, 2024
2024-10-10 17:24U:BPTHNews ReleaseBio-Path Holdings Announces Closing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
2024-10-08 20:00U:BPTHNews ReleaseBio-Path Holdings Announces $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
2024-10-08 07:00U:BPTHNews ReleaseBio-Path Holdings Initiates Development of Therapeutic Program for Treatment of Obesity
2024-09-16 07:00U:BPTHNews ReleaseBio-Path Holdings Announces Publication in Biomedicines
2024-09-04 17:49U:BPTHNews ReleaseStonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q2 24
2024-09-03 07:00U:BPTHNews ReleaseBio-Path Holdings to Present at H.C. Wainwright 26th Annual Global Investment Conference
2024-08-21 07:00U:BPTHNews ReleaseBio-Path Holdings Reports Solid Tumor Patient Response Supporting BP1001-A's Compelling Potential as Treatment for Advanced Solid Tumors
2024-08-15 07:00U:BPTHNews ReleaseBio-Path Holdings Reports Second Quarter 2024 Financial Results